2008 Press Releases
December 9th, 2008
ChemGenex’s Omacetaxine Demonstrates 80% Complete Hematological Response Rate in Drug-Resistant CML Patients with the T315I Mutation
September 17th, 2008
ChemGenex Completes $A12.9 Million Capital Raising
August 5th, 2008
ChemGenex Appoints Jean-Luc Tétard to Board of Directors
July 1st, 2008
ChemGenex Announces Submission of Non-Clinical Section of Rolling NDA for Omacetaxine
June 16th, 2008
ChemGenex’s Omacetaxine Demonstrates Activity in CML Patients Who Have Failed Therapy with Multiple Tyrosine Kinase Inhibitors
June 10th, 2008
ChemGenex Acquires Full Control of Omacetaxine, Consolidating the Product’s Global Rights
May 12th, 2008
Australian Taxation Office Class Ruling on Demerger
April 15th, 2008
ChemGenex Reports Oral Bioavailability of Omacetaxine and Expands on Mechanism of Action
April 14th, 2008
ChemGenex Confirms Planned NDA Rolling Submission for Omacetaxine Following Meeting with U.S. FDA
January 7th, 2008